Korean Medication Algorithm for Depressive Disorders 2017: Third Revision
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, Jeong Seok | - |
dc.contributor.author | Bahk, Won-Myong | - |
dc.contributor.author | Wang, Hee Ryung | - |
dc.contributor.author | Woo, Young Sup | - |
dc.contributor.author | Park, Young-Min | - |
dc.contributor.author | Jeong, Jong-Hyun | - |
dc.contributor.author | Kim, Won | - |
dc.contributor.author | Shim, Se-Hoon | - |
dc.contributor.author | Lee, Jung Goo | - |
dc.contributor.author | Jon, Duk-In | - |
dc.contributor.author | Min, Kyung Joon | - |
dc.date.accessioned | 2021-08-11T12:43:49Z | - |
dc.date.available | 2021-08-11T12:43:49Z | - |
dc.date.issued | 2018-02 | - |
dc.identifier.issn | 1738-1088 | - |
dc.identifier.issn | 2093-4327 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/6249 | - |
dc.description.abstract | Objective: In 2002, the Korean Society for Affective Disorders developed the guidelines for the treatment of major depressive disorder (MDD), and revised it in 2006 and 2012. The third revision of these guidelines was undertaken to reflect advances in the field. Methods: Using a 44-item questionnaire, an expert consensus was obtained on pharmacological treatment strategies for MDD 1) without or 2) with psychotic features, 3) depression subtypes, 4) maintenance, 5) special populations, 6) the choice of an antidepressant (AD) regarding safety and adverse effects, and 7) non-pharmacological biological therapies. Recommended first, second, and third-line strategies were derived statistically. Results: AD monotherapy is recommended as the first-line strategy for non-psychotic depression in adults, children/adolescents, elderly adults, patient with persistent depressive disorder, and pregnant women or patients with postpartum depression or premenstrual dysphoric disorder. The combination of AD and atypical antipsychotics (AAP) was recommended for psychotic depression in adult, child/adolescent, postpartum depression, and mixed features or anxious distress. Most experts recommended stopping the ongoing initial AD and AAP after a certain period in patients with one or two depressive episodes. As an MDD treatment modality, 92% of experts are considering electroconvulsive therapy and 46.8% are applying it clinically, while 86% of experts are considering repetitive transcranial magnetic stimulation but only 31.6% are applying it clinically. Conclusion: The pharmacological treatment strategy in 2017 is similar to that of Korean Medication Algorithm for Depressive Disorder 2012. The preference of AAPs was more increased. | - |
dc.format.extent | 21 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한정신약물학회 | - |
dc.title | Korean Medication Algorithm for Depressive Disorders 2017: Third Revision | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.9758/cpn.2018.16.1.67 | - |
dc.identifier.scopusid | 2-s2.0-85041640519 | - |
dc.identifier.wosid | 000425540200009 | - |
dc.identifier.bibliographicCitation | Clinical Psychopharmacology and Neuroscience, v.16, no.1, pp 67 - 87 | - |
dc.citation.title | Clinical Psychopharmacology and Neuroscience | - |
dc.citation.volume | 16 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 67 | - |
dc.citation.endPage | 87 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002320698 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | SEROTONIN REUPTAKE INHIBITORS | - |
dc.subject.keywordPlus | PSYCHIATRY WFSBP GUIDELINES | - |
dc.subject.keywordPlus | CARE GLAD-PC | - |
dc.subject.keywordPlus | CLINICAL GUIDELINES | - |
dc.subject.keywordPlus | ANXIETY TREATMENTS | - |
dc.subject.keywordPlus | CANADIAN NETWORK | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | ANTIDEPRESSANT TREATMENT | - |
dc.subject.keywordPlus | ADOLESCENT DEPRESSION | - |
dc.subject.keywordPlus | BIOLOGICAL TREATMENT | - |
dc.subject.keywordAuthor | Algorithms | - |
dc.subject.keywordAuthor | Depressive disorder | - |
dc.subject.keywordAuthor | Drug therapy | - |
dc.subject.keywordAuthor | Guideline | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.